內(nèi)皮細(xì)胞特異分子1(ESM1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Endothelial Cell Specific Molecule 1 (ESM1)
Endocan
- 編號SEC463Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時長3h
- 檢測范圍0.156-10ng/mL
- 靈敏度最小可檢測劑量小于等于0.057ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3192 ¥ 4560 ¥ 20520 ¥ 38760 ¥ 319200
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測內(nèi)皮細(xì)胞特異分子1(ESM1)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的內(nèi)皮細(xì)胞特異分子1(ESM1)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 81-88 | 84 |
| EDTA plasma(n=5) | 88-96 | 93 |
| heparin plasma(n=5) | 79-99 | 93 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的內(nèi)皮細(xì)胞特異分子1(ESM1)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中內(nèi)皮細(xì)胞特異分子1(ESM1)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-101% | 80-92% | 94-102% | 93-104% |
| EDTA plasma(n=5) | 98-105% | 78-97% | 87-95% | 81-96% |
| heparin plasma(n=5) | 81-104% | 96-103% | 93-101% | 83-102% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100µL，37°C孵育1小時；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將內(nèi)皮細(xì)胞特異分子1(ESM1)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的內(nèi)皮細(xì)胞特異分子1(ESM1)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的內(nèi)皮細(xì)胞特異分子1(ESM1)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的內(nèi)皮細(xì)胞特異分子1(ESM1)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值)，計(jì)算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPC463Ra01 | 內(nèi)皮細(xì)胞特異分子1(ESM1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC463Ra01 | 內(nèi)皮細(xì)胞特異分子1(ESM1)多克隆抗體 | WB; IHC; ICC; IP. |
| LAC463Ra71 | 內(nèi)皮細(xì)胞特異分子1(ESM1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEC463Ra | 內(nèi)皮細(xì)胞特異分子1(ESM1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC463Ra | 內(nèi)皮細(xì)胞特異分子1(ESM1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Urology | Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantation [PubMed: 22608803] |
| Microvasc Res. | Endocan is useful biomarker of survival and severity in sepsis. [Pubmed: 24769132] |
| J Matern Fetal Neonatal Med. | Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes [Pubmed:25211383] |
| Microvasc Res. | Endocan is useful biomarker of survival and severity in sepsis [Pubmed:24769132] |
| Angiology | Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus [PubMed: 26614790] |
| Archives of Medical Science - Atherosclerotic Diseases | Assessment of subclinical cardiac damage in chronic plaque psoriasis patients: a case control study [Journal:-102] |
| Int Immunopharmacol.? | Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension. [pubmed:27912147] |
| Oncotarget | Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer [pubmed:28514746] |
| Biomedical and Pharmacology Journal | Changes in Endocan Levels and Blood Coagulation in HIV Infection [DOI: 10.13005/bpj/1082] |
| Life Sciences | A novel role of endocan in alleviating LPS-induced acute lung injury [Pubmed:29627442] |
| International Urology and Nephrology | Is the plasma endocan level a reliable predictor for the severity of erectile dysfunction? [Pubmed:30054863] |
| The Open Rheumatology Journal | Serum Level of Endothelial Cell-Specific Molecule-1 (ESM-1) as a New Potential Biomarker for Rheumatoid Arthritis Disease Activity [Doi: 10.2174/1874312901812010189] |
| Molecular?Medicine?Reports | Downregulation of ENDOCAN in myeloid leukemia cells inhibits proliferation and promotes apoptosis by suppressing nuclear factor?κB activity [Pubmed: 30816462] |
| Biomarkers in Medicine | Endothelial biomarkers in the light of new sepsis definition [Pubmed: 30920847] |
| Experimental and Therapeutic Medicine | Risk stratification and prognostic evaluation of endothelial cell?specific molecule1, von Willebrand factor, and a disintegrin?like and metalloprotease with?… [] |
| Turkish Journal of Medical Sciences | A novel marker relationship between carotid intima–media thickness and disease activity score-28 in patients with rheumatoid arthritis: human endothelial cell?… [Pubmed: 31655533] |
| Biomarkers | Role of Ascitic Endocan Levels in the Diagnosis of Spontaneous Bacterial Peritonitis in Decompensated Cirrhosis [Pubmed: 32364003] |
| J Obstet Gynaecol Res | Comparison of the maternal serum endocan levels in preterm premature rupture of membrane and normal pregnancy [34109715] |
| turkish journal clinics laboratory | The relationship between serum endocan levels with the presence of contrast-induced nephropathy in patients undergoing coronary angiography [] |
